Skip to content
Home/Companies/Biotech/Relation Therapeutics
Relation Therapeutics

Relation Therapeutics

Biotech·United Kingdom·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns Relation Therapeutics?

Relation Therapeutics is currently owned by Hitachi Ventures through Hitachi Ventures Fund III (2023 vintage), since 2024.

Hand-verified · updated 2026-07-16

Hitachi Ventures
Investor
Hitachi Ventures
Hitachi Ventures Fund III · 2023 · VC

Key facts

HQUnited Kingdom
SectorBiotech
StatusActive
Websitewww.relationrx.com

More from Hitachi Ventures Fund III

Other portfolio companies in the same fund.

Bioptimus
Bioptimus
Active
BiotechFrance· 2025
Archetype AI
Active
Deep TechUnited States· 2024
Cure51
Cure51
Active
BiotechFrance· 2024
Cyclic Materials
Active
IndustrialsCanada· 2024
Ema
Ema
Active
SoftwareUnited States· 2024
Grow Inc
Grow Inc
Active
FintechAustralia· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Relation Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Relation Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue